Toxicology News and Research

Latest Toxicology News and Research

Prenatal exposure to BPA linked with wheezing in children

If a pregnant woman is exposed to bisphenol A, especially during the first trimester, her child may be at higher risk of wheezing early in life, according to a study to be presented Sunday, May 1, at the Pediatric Academic Societies annual meeting in Denver.

2 May 2011

Gene therapy approach using CD59 shows promise against AMD: Study

A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration, according to a new in vivo study by researchers at Tufts University School of Medicine.

30 Apr 2011

Unintentional prescription opioid overdose deaths have reached epidemic proportions in the U.S.

Unintentional overdose deaths in teens and adults have reached epidemic proportions in the U.S. In some 20 states in 2007 the number of unintentional drug poisoning deaths exceeded either motor vehicle crashes or suicides, two of the leading causes of injury death.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

Halfpenny adds 13 new clients for clinical data connectivity in first quarter 2011

Halfpenny Technologies, Inc., a leading provider of clinical data exchange solutions, today announced that during the first quarter of 2011, it has added 13 new clients to its growing customer list.

22 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Convergence initiates CNV2197944 Phase I study in chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun.

22 Apr 2011

Scientists discover critical pathway in the brain linked to stress response

A team of neuroscientists at the University of Leicester, UK, in collaboration with researchers from Poland and Japan, has announced a breakthrough in the understanding of the 'brain chemistry' that triggers our response to highly stressful and traumatic events.

21 Apr 2011

Existing scientific evidence indicates no risk to human health from BPA exposure

The North American Metal Packaging Alliance, Inc. urges policymakers and media to take heed of a decisive analysis by independent toxicologists that concludes bisphenol A (BPA) poses no risk to human health.

20 Apr 2011

Breakdown products of thalidomide cause birth defects: New study

Thalidomide may have been withdrawn in the early 1960s for use by pregnant women, but its dramatic effects remain memorable half a century later. Now, researchers have taken a major step toward understanding exactly how thalidomide causes the birth defects.

20 Apr 2011

Radiation leaked from Japan's nuclear power plant does not pose immediate public health risk, WHO says

The decision on Tuesday by Japan's Nuclear and Industrial Safety Agency to increase the level of severity at the Fukushima Daiichi nuclear power plant "does not mean the public health risk is any worse or that the disaster resembles Chernobyl in 1986," the WHO and other agencies said in response to the announcement, Reuters reports.

15 Apr 2011

RXi Pharmaceuticals acquires Apthera

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.

15 Apr 2011

Toxic substances including arsenic in baby food

The latest reports have revealed that there are small amounts of arsenic and other toxins that are found in soil, creeping into the ingredients used in top-selling baby foods. Manufacturers insist the levels are so low they do not pose a health risk. But scientists and food campaigners are calling for efforts to eliminate the chemicals from mass-produced products eaten by millions of young babies. Leading brands from Organix, Hipp, Nestle and Holle were tested by Swedish researchers.

10 Apr 2011

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

The meeting Experimental Biology 2011 (EB 2011) begins April 9 and runs through April 13 at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

CoMeD urges UN to ban mercury use in pharmaceuticals

While the United Nations actively questions the use of a vaccine preservative that contains the known neurotoxin mercury, the Coalition for Mercury-Free Drugs, a Maryland-based, non-profit organization, is urging the UN to ban it.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

BioLife Solutions first quarter revenue is $611,000 for March 31, 2011

BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31, 2011.

6 Apr 2011

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Neurocrine Biosciences, Inc. announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

6 Apr 2011

Toxicology News and Research

Latest Toxicology News and Research

Prenatal exposure to BPA linked with wheezing in children

Gene therapy approach using CD59 shows promise against AMD: Study

Unintentional prescription opioid overdose deaths have reached epidemic proportions in the U.S.

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

Halfpenny adds 13 new clients for clinical data connectivity in first quarter 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Convergence initiates CNV2197944 Phase I study in chronic pain

Scientists discover critical pathway in the brain linked to stress response

Existing scientific evidence indicates no risk to human health from BPA exposure

Breakdown products of thalidomide cause birth defects: New study

Radiation leaked from Japan's nuclear power plant does not pose immediate public health risk, WHO says

RXi Pharmaceuticals acquires Apthera

Toxic substances including arsenic in baby food

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

CoMeD urges UN to ban mercury use in pharmaceuticals

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

BioLife Solutions first quarter revenue is $611,000 for March 31, 2011

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Toxicology News and Research

Latest Toxicology News and Research

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in